Psychedelic Funding Update: Q2 2024
We have updated our Psychedelic Company Financing Tracker to reflect activity in Q2 2024. You can explore the interactive charts here.
As a reminder, Q1 2024 got off to a roaring start, with a small crop of substantial rounds such as Lykos Therapeutics’ $100m+ Series A as well as both Cybin and MindMed’s significant public offerings.
To be sure, valuations for these rounds were markedly more modest than those seen a few years ago, but the return of significant investment to the space was seen as a welcome signal for investors and operators alike.
The momentum from Q1 2024 was not quite sustained in Q2, however, with aggregate investment dropping to just over $175m. That’s nothing to be sniffed at, however, as the last time we saw a quarter with this level of investment—aside from Q1—was Q4 2022...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks